August 9, 2022 Life Science Tools Product Launch

QIAGEN launches new solutions that significantly accelerate DNA variant detection and RNA sequencing of low-input samples

August 9, 2022 QIAseq Targeted DNA Pro Panels halve library preparation time for sequencing samples New low-input kit for RNA sequencing further expands QIAGEN’s universal NGS portfolio and reduces disposable plastics use by 90%  Four million samples have been processed by growing range of QIAseq NGS panels running on any sequencer Hilden, Germany, and Germantown,... Read more

March 3, 2021 Clinical Research/Diagn. Product Launch

QIAGEN launches QIAsphere cloud-based connectivity solution to enhance QIAstat-Dx capabilities in digital diagnostics

Hilden, Germany, and Germantown, Maryland, March 3, 2021 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week. QIAsphere sets new standards for syndromic testing digital health, providing users with... Read more

March 2, 2021 Clinical Research/Diagn. Product Launch

QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs

Germantown, Maryland, and Hilden, Germany, March 02, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other markets worldwide.... Read more

February 24, 2021 Clinical Research/Diagn. Lab Top-10 Life Science Tools M&A, Partnerships

QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia

PLYMOUTH MEETING, PA., USA, and GERMANTOWN, MD., USA, and HILDEN, Germany, February 24, 2021 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement... Read more

February 18, 2021 Lab Top-10 Licensing, IP, and Legal M&A, Partnerships

QIAGEN announces Digital Partner Program with five initial partnerships

Redwood City, California, and Hilden, Germany, February 18, 2021 – QIAGEN today announced the launch of the QIAGEN Digital Insights Partnership program for genomic vendors to leverage QIAGEN’s genomic content and analysis leadership to expand customer access and deliver extended genomic solutions for scientists and clinicians. The first group of five new partnerships involves DNAnexus,... Read more

February 9, 2021 PAI Top-10 PR/Corporate

QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021

Venlo, the Netherlands, February 9, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the fourth quarter and full-year 2020, exceeding the goals for net sales and adjusted earnings per share. Net sales in the fourth quarter of 2020 rose 38% (+36% at constant exchange rates, CER) to... Read more

January 28, 2021 Acad, Gov/Utilities Environ, Ag./Food & Bev Life Science Tools Liq. Handling & Robotics

QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing

Germantown, Maryland, and Hilden, Germany, January 28, 2021 – QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products. The use of dPCR in the worldwide surveillance of COVID-19 is an additional step towards making digital PCR (dPCR) an affordable and standard instrument for a host of applications... Read more

January 20, 2021 PR/Corporate

QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021

GERMANTOWN, Maryland, and HILDEN, Germany, January 20 2021–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in... Read more

January 20, 2021 Life Science Tools PAI Top-10

QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus

Germantown, Maryland, and Hilden, Germany, January 20, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections – and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established... Read more